SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ: VTYX), a biopharmaceutical company engaged in developing novel oral therapies for inflammatory diseases, has announced results from the Phase 2 trial of its drug candidate VTX002. The findings were presented at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) in Stockholm, Sweden.
The study focused on VTX002, an oral selective sphingosine-1-phosphate-1 receptor modulator, and its efficacy and safety in treating moderately to severely active ulcerative colitis. The trial was randomized, double-blind, and placebo-controlled, aiming to establish VTX002 as a potential oral treatment option with a favorable safety profile.
Raju Mohan, CEO of Ventyx, expressed optimism about the drug's profile, citing a "potentially differentiated rate of endoscopic remission and histologic-endoscopic mucosal improvement" as well as its potential for being a best-in-class safety option.
The presentation, led by Dr. Bruce E. Sands of the Icahn School of Medicine at Mount Sinai, NY, discussed the outcomes of the trial, which could represent a significant development for patients with ulcerative colitis, a chronic inflammatory bowel disease.
While Ventyx has cautioned against placing undue reliance on forward-looking statements, the company has underscored its commitment to addressing unmet medical needs through the development of oral immunology therapies. Ventyx's pipeline includes other internally discovered clinical programs targeting various immune-related pathways.
The results from the trial are expected to contribute to the ongoing research and development efforts in the field of autoimmune and inflammatory disorders. Ventyx's focus remains on providing novel oral treatments that could potentially transition immunology markets from injectable to oral drugs.
The data from the VTX002 trial is now available in the Investors section of Ventyx's website. The company continues to navigate the challenges of clinical development, including the inherent risks and uncertainties of trial outcomes and regulatory processes.
This report is based on a press release statement from Ventyx Biosciences, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.